Placental Development & Physiology

Foundations and mechanisms

Implantation, trophoblast differentiation, and villous maturation

Placental development begins when the blastocyst implants into a progesterone-primed endometrium approximately 6–10 days after fertilization. The trophoblast differentiates into an inner, mitotically active cytotrophoblast and an outer invasive syncytiotrophoblast. The syncytiotrophoblast erodes maternal endometrial tissue and maternal sinusoids, creating lacunae that become the early intervillous spaces. This is the basis of the human hemochorial placenta, in which maternal blood directly bathes chorionic villi.

Developmental stage	Approximate timing	Key event
Primary villi	Day 13	Cytotrophoblast columns extend into syncytiotrophoblast
Secondary villi	Day 16	Extraembryonic mesoderm invades villous core
Tertiary villi	Day 21	Fetal capillaries form; fetoplacental circulation begins
Mature placenta	By 18–20 weeks	Extensive branching villi and remodeled spiral arteries

The embryonic portion of the placenta is the chorion frondosum, derived from villi adjacent to the decidua basalis. Villi on the opposite side regress to form the chorion laeve. The maternal portion is the decidua basalis; the decidua capsularis overlies the conceptus, and the decidua parietalis lines the remaining uterine cavity. At term, the placenta is approximately 15–20 cm in diameter, 2–3 cm thick, weighs about 500 g, and contains roughly 15–20 cotyledons.

Spiral artery remodeling and placental perfusion

Normal placentation requires extravillous cytotrophoblast invasion of the maternal decidua and inner myometrium. These cells remodel high-resistance spiral arteries into low-resistance, high-capacitance vessels. Remodeling occurs in waves, classically around 8–12 weeks and again around 16–18 weeks. At term, uteroplacental blood flow is approximately 500–750 mL/min, representing about 10% of maternal cardiac output.

Inadequate trophoblast invasion leads to persistently narrow, vasoreactive spiral arteries, causing placental ischemia and oxidative stress. This mechanism underlies high-yield disorders such as preeclampsia, fetal growth restriction, and placental abruption. In contrast, abnormal adherence of villi to the myometrium occurs when the decidua basalis and fibrinoid Nitabuch layer are deficient, producing the placenta accreta spectrum: accreta attaches to myometrium, increta invades myometrium, and percreta penetrates through the uterine serosa.

Placental exchange and barrier physiology

The placental barrier separates maternal blood in the intervillous space from fetal blood in villous capillaries. Early in gestation it includes syncytiotrophoblast, cytotrophoblast, connective tissue, and fetal capillary endothelium; later, cytotrophoblast becomes discontinuous and the barrier thins to approximately 2–5 μm, improving diffusion. The umbilical cord normally contains 2 umbilical arteries carrying deoxygenated fetal blood to the placenta and 1 umbilical vein carrying oxygenated blood to the fetus.

Substance	Main transport mechanism	High-yield principle
O2, CO2	Simple diffusion	Driven by gradients; fetal Hb has higher O2 affinity due to reduced 2,3-BPG binding
Glucose	Facilitated diffusion via GLUT1	Maternal hyperglycemia increases fetal glucose exposure
Amino acids, calcium, iron	Active transport	Fetal concentrations may exceed maternal concentrations
IgG	Fc receptor-mediated transcytosis	Begins after ~13 weeks; greatest in third trimester; IgM does not cross well
Drugs/toxins	Usually passive diffusion	Lipid-soluble, nonionized, low-molecular-weight drugs <500 Da cross most readily

Fetal oxygenation is efficient despite a low fetal arterial PO₂. Umbilical venous PO₂ is only about 30–35 mm Hg, but fetal hemoglobin maintains relatively high saturation because HbF binds oxygen more avidly than adult hemoglobin. The double Bohr effect further favors transfer: maternal CO₂ loss increases maternal Hb oxygen affinity less, while fetal CO₂ loss increases fetal Hb affinity more, enhancing fetal oxygen uptake.

Endocrine functions of the placenta

The syncytiotrophoblast secretes human chorionic gonadotropin, which maintains the corpus luteum until placental steroidogenesis is sufficient. hCG is detectable in maternal serum approximately 8–11 days after conception, roughly doubles every 48 hours in early viable intrauterine pregnancy, peaks at 8–10 weeks near 100,000 mIU/mL, then declines. The luteal-placental shift occurs around 7–9 weeks, when the placenta produces enough progesterone to maintain the endometrium independently.

Placental steroidogenesis is a “fetal-placental unit.” The placenta converts maternal cholesterol to progesterone but lacks significant 17α-hydroxylase/17,20-lyase, so it cannot efficiently synthesize androgens de novo. For estrogen production, especially estriol, it relies on fetal adrenal production of DHEA-S and fetal hepatic hydroxylation. Therefore, estriol reflects integrated fetal adrenal, fetal liver, and placental function.

Other placental hormones include human placental lactogen, which induces maternal insulin resistance and lipolysis to increase nutrient availability for the fetus; CRH, which rises near term; and progesterone, which suppresses uterine contractions and promotes immune tolerance. The syncytiotrophoblast lacks classical MHC expression, while extravillous trophoblast expresses nonclassical HLA-G, helping protect the semiallogeneic fetus from maternal immune rejection.

Clinical assessment and investigations

Clinical presentations suggesting abnormal placentation or placental function

Placental disorders are suspected clinically when normal trophoblast invasion, chorionic villus development, or placental endocrine/transport function is impaired. The placenta normally anchors to decidua basalis, remodels maternal spiral arteries into low-resistance vessels, and secretes hormones such as hCG, human placental lactogen, progesterone, estrogens, and placental growth factor. Failure of these processes produces characteristic clinical syndromes.

• Early pregnancy bleeding or pain: consider spontaneous abortion, ectopic pregnancy, gestational trophoblastic disease, subchorionic hematoma, or implantation bleeding.
• Painless third-trimester bleeding: classically suggests placenta previa, in which placental tissue overlies or approaches the internal cervical os.
• Painful third-trimester bleeding with uterine tenderness: suggests placental abruption, premature separation of placenta from the uterine wall; risk factors include hypertension, cocaine use, trauma, smoking, and prior abruption.
• Hypertension after 20 weeks with proteinuria or end-organ findings: suggests preeclampsia, linked to shallow trophoblast invasion and high-resistance uteroplacental blood flow.
• Small-for-gestational-age fetus or oligohydramnios: suggests uteroplacental insufficiency, because reduced placental perfusion limits fetal oxygen and nutrient delivery.
• Excessive uterine size, hyperemesis, very high hCG, or “snowstorm” ultrasound: suggests hydatidiform mole, a disorder of abnormal trophoblastic proliferation.

Core investigations and interpretation

Test	High-yield interpretation
Quantitative serum β-hCG	Detectable about 8–11 days after ovulation. In early viable intrauterine pregnancy, β-hCG typically rises by at least ~35–53% in 48 hours; slower rise suggests ectopic or failing pregnancy. Peaks at 8–10 weeks, then declines. Very high levels suggest multifetal gestation or molar pregnancy.
Transvaginal ultrasound	Gestational sac usually visible when β-hCG exceeds the discriminatory zone, approximately 1500–3500 mIU/mL. Absence of intrauterine pregnancy above this range raises concern for ectopic pregnancy, but dates, assay variation, and multifetal pregnancy must be considered.
Serum progesterone	Reflects corpus luteum and later placental steroidogenesis. Very low levels, often <5 ng/mL, strongly suggest nonviable pregnancy; levels >20–25 ng/mL support viability but do not localize the pregnancy.
Maternal serum α-fetoprotein	Measured mainly at 15–20 weeks. Elevated in open neural tube defects, abdominal wall defects, multiple gestation, fetal demise, and incorrect dating; decreased in trisomy 21.
Ultrasound placental localization	Evaluates previa, accreta spectrum, subchorionic hemorrhage, placental lakes, and fetal growth. Transvaginal ultrasound is more accurate than transabdominal for placental edge-to-os distance and is not contraindicated when performed properly.
Doppler velocimetry	Assesses vascular resistance. Abnormal uterine artery notching or elevated pulsatility suggests impaired spiral artery remodeling. Umbilical artery absent or reversed end-diastolic flow indicates severe placental resistance and fetal compromise.

Placental biomarkers in aneuploidy screening

Many prenatal screening markers are placental products; abnormal values reflect altered trophoblast biology rather than direct fetal organ dysfunction. Step 1 questions often test direction of marker changes.

Condition	Typical screening pattern	Mechanistic association
Trisomy 21	First trimester: ↓ PAPP-A, ↑ β-hCG. Quad screen: ↓ AFP, ↓ unconjugated estriol, ↑ β-hCG, ↑ inhibin A.	Abnormal placental trophoblast function increases hCG and inhibin A; fetal hepatic AFP and placental estriol pathway are reduced.
Trisomy 18	↓ AFP, ↓ β-hCG, ↓ unconjugated estriol, often ↓ inhibin A.	Globally reduced fetoplacental function.
Open neural tube defect	↑ maternal serum AFP; acetylcholinesterase may be present in amniotic fluid.	Fetal serum proteins leak into amniotic fluid and maternal circulation.

Cell-free fetal DNA testing analyzes placental trophoblast-derived DNA fragments in maternal plasma and can be performed from about 10 weeks. It has very high sensitivity and specificity for common trisomies, especially trisomy 21, often >99% sensitivity, but remains a screening test because confined placental mosaicism can produce discordant results. Diagnostic confirmation requires chorionic villus sampling or amniocentesis.

Differential diagnosis by clinical pattern

Clinical pattern	Key differentials	Distinguishing investigations
First-trimester bleeding with positive pregnancy test	Threatened abortion, ectopic pregnancy, molar pregnancy, implantation bleeding	Serial β-hCG, transvaginal ultrasound, Rh status, CBC if significant bleeding
Markedly elevated β-hCG, enlarged uterus, hyperemesis	Complete mole, partial mole, multifetal gestation	Ultrasound; complete mole shows diffuse villous swelling and absent fetus; partial mole may show abnormal fetus and triploidy
Painless late pregnancy bleeding	Placenta previa, vasa previa, cervical lesion	Ultrasound placental location; avoid digital cervical examination until previa excluded
Painful bleeding, contractions, fetal distress	Placental abruption, uterine rupture, labor with bloody show	Clinical diagnosis; ultrasound has limited sensitivity for abruption because acute blood can be isoechoic

Placental insufficiency and preeclampsia thresholds

Preeclampsia is defined as new hypertension after 20 weeks’ gestation: systolic blood pressure ≥140 mm Hg or diastolic ≥90 mm Hg on two occasions, plus proteinuria or end-organ dysfunction. Proteinuria is ≥300 mg/24 hours, urine protein/creatinine ratio ≥0.3, or dipstick 1+ if quantitative testing is unavailable. Severe-range blood pressure is ≥160 systolic or ≥110 diastolic. Pathophysiologically, inadequate extravillous trophoblast invasion leaves spiral arteries narrow and vasoreactive, causing placental ischemia, antiangiogenic factor release, systemic endothelial dysfunction, and fetal growth restriction.

Fetal growth restriction is commonly defined as estimated fetal weight below the 10th percentile for gestational age; below the 3rd percentile is more severe. Investigation emphasizes accurate dating, anatomic ultrasound, amniotic fluid volume, and Doppler flow. In placental resistance, umbilical artery end-diastolic flow decreases; absent or reversed end-diastolic flow is a high-yield marker of severe uteroplacental disease.

Management, pharmacology and procedures

Principles of managing placental dysfunction

Many obstetric complications are ultimately disorders of placental implantation, perfusion, or separation. For Step 1, the key concept is that the only definitive treatment for severe placental disease threatening the mother or fetus is delivery; temporizing therapy is used to stabilize the mother, prolong pregnancy when safe, and reduce fetal morbidity from prematurity. Initial evaluation of suspected placental pathology generally includes maternal vital signs, abdominal examination, fetal heart rate assessment, ultrasound for placental location and fetal growth, and laboratory assessment when bleeding or preeclampsia is suspected.

Clinical problem	Placental mechanism	High-yield management principle
Preeclampsia	Abnormal spiral artery remodeling → high-resistance uteroplacental flow → endothelial dysfunction	Definitive treatment is delivery; magnesium sulfate prevents seizures; antihypertensives reduce maternal stroke risk
Placenta previa	Placenta overlies or approaches internal cervical os	Do not perform digital cervical examination until previa is excluded by ultrasound
Placental abruption	Premature placental separation → maternal hemorrhage and fetal hypoxia	Maternal stabilization first; monitor for disseminated intravascular coagulation
Placenta accreta spectrum	Defective decidua basalis → excessive trophoblastic invasion into myometrium	Plan delivery with blood products available; cesarean hysterectomy may be required
Fetal growth restriction	Placental insufficiency → reduced nutrient and oxygen transfer	Serial growth ultrasound and Doppler surveillance; delivery if testing becomes nonreassuring

Prevention and surveillance

Low-dose aspirin decreases the risk of preeclampsia in high-risk pregnancies by inhibiting platelet thromboxane A₂ production and improving the prostacyclin-to-thromboxane balance. Current guidelines recommend aspirin 81 mg orally daily, started between 12 and 28 weeks’ gestation, optimally before 16 weeks, and continued until delivery in patients at high risk, such as those with prior preeclampsia, chronic hypertension, diabetes mellitus, renal disease, autoimmune disease, or multifetal gestation.

Placental insufficiency is monitored using fetal growth ultrasound and umbilical artery Doppler velocimetry. In normal placental development, trophoblast invasion lowers downstream resistance, allowing continuous diastolic flow. Absent or reversed end-diastolic flow indicates markedly increased placental vascular resistance and is associated with fetal hypoxemia, acidosis, and stillbirth risk.

Rh(D) alloimmunization prophylaxis

Rh disease is a classic placenta-related immunologic disorder. An Rh-negative mother exposed to Rh-positive fetal red blood cells can form anti-D IgG, which crosses the placenta in later pregnancies and causes fetal hemolytic disease. Prevention uses passive antibody to clear fetal Rh-positive cells before maternal sensitization.

Intervention	Typical dose	Timing	Key fact
Rh(D) immune globulin	300 micrograms IM	Routinely at 28 weeks and within 72 hours postpartum if infant is Rh-positive	Covers approximately 30 mL fetal whole blood or 15 mL fetal RBCs
Early pregnancy bleeding/procedure prophylaxis	Often 50 micrograms before 12 weeks or 300 micrograms if smaller dose unavailable	After miscarriage, ectopic pregnancy, chorionic villus sampling, amniocentesis, trauma, or bleeding	Prevents primary maternal anti-D formation
Kleihauer-Betke test	Not a drug	After large fetomaternal hemorrhage	Quantifies fetal RBCs to determine additional RhIG dosing

Medications used when placental disease threatens preterm delivery

When delivery before term is likely, medications are directed at fetal organ maturation and maternal stabilization. These drugs do not “fix” the placenta; they reduce complications of prematurity or severe maternal disease.

Drug/class	Dose commonly tested	Mechanism	High-yield adverse effects/contraindications
Betamethasone	12 mg IM every 24 hr for 2 doses	Glucocorticoid induces fetal type II pneumocyte surfactant production	Given when preterm birth risk is high, classically 24 0/7–33 6/7 weeks
Dexamethasone	6 mg IM every 12 hr for 4 doses	Same as above	Alternative antenatal corticosteroid regimen
Magnesium sulfate	Loading 4–6 g IV, then 1–2 g/hr IV	Decreases neuromuscular excitability; prevents eclamptic seizures; fetal neuroprotection before early preterm delivery	Toxicity: loss of deep tendon reflexes, respiratory depression; antidote calcium gluconate 1 g IV
Nifedipine	Often 10–20 mg PO, then repeated dosing	L-type calcium channel blocker → uterine smooth muscle relaxation	Maternal hypotension, headache; used for short-term tocolysis
Indomethacin	Often 50–100 mg loading, then 25–50 mg every 6 hr	COX inhibitor → decreased prostaglandin-mediated contractions	Avoid later gestation due to premature ductus arteriosus closure and oligohydramnios

Procedures involving the placenta and amniotic cavity

Cell-free fetal DNA testing analyzes placental trophoblast DNA fragments in maternal blood after approximately 10 weeks. It is a highly sensitive screening test for trisomy 21, often reported with sensitivity above 99%, but it is not diagnostic because the DNA is placental in origin and can be affected by confined placental mosaicism.

Chorionic villus sampling obtains placental trophoblast tissue for genetic diagnosis at 10–13 weeks. It provides earlier karyotype or molecular diagnosis than amniocentesis but cannot assess amniotic fluid alpha-fetoprotein for open neural tube defects. Performing CVS before 10 weeks is associated with limb reduction defects.

Amniocentesis is typically performed at or after 15 weeks. It samples amniotic fluid containing fetal cells and can measure alpha-fetoprotein and acetylcholinesterase, which are increased in open neural tube defects. Both CVS and amniocentesis can cause fetomaternal hemorrhage; Rh-negative patients should receive Rh(D) immune globulin.

Management of delivery and postpartum placental complications

Placental separation normally occurs in the third stage of labor. Failure of uterine contraction or retained placental tissue can cause postpartum hemorrhage. First-line therapy is uterine massage and oxytocin, commonly 10 units IM or 10–40 units diluted IV infusion. Additional uterotonics include methylergonovine 0.2 mg IM, avoided in hypertension because it causes vasoconstriction; carboprost 250 micrograms IM every 15–90 minutes to a maximum of 2 mg, avoided in asthma due to bronchoconstriction; and misoprostol 600–1000 micrograms via oral, sublingual, or rectal routes. Persistent bleeding may require manual removal of retained placenta, uterine tamponade, transfusion, or surgery.

Exam controversies and advanced synthesis

Placental biomarkers: useful physiology, not stand-alone diagnoses

The placenta is both an endocrine organ and a vascular exchange organ; many “screening tests” exploit trophoblast-derived molecules but require careful interpretation. hCG is produced by syncytiotrophoblast, detectable in maternal serum about 8–10 days after ovulation, detectable in urine near the missed period, rises approximately every 48 hours early in pregnancy, and peaks at 8–10 weeks. Abnormally low or slowly rising hCG suggests ectopic pregnancy or early pregnancy loss, but Step 1 questions usually test mechanism rather than management. Human placental lactogen increases maternal insulin resistance and lipolysis, shunting glucose to the fetus; this explains the diabetogenic effect of pregnancy. Estriol synthesis requires fetal adrenal DHEA-S, fetal liver modification, and placental aromatase; therefore low estriol can reflect fetal, placental, or aneuploid pathology.

Test or marker	Placental basis	High-yield interpretation
Cell-free fetal DNA	Mostly trophoblast-derived DNA in maternal plasma	Screening, not diagnostic; commonly performed after 10 weeks; fetal fraction usually must be ≥4%. Trisomy 21 sensitivity and specificity are typically >99%, but positive predictive value depends on maternal age/pretest probability.
Low PAPP-A	Abnormal trophoblast/placental development	Associated with trisomy 21 and placental insufficiency syndromes; not independently diagnostic.
Low unconjugated estriol	Requires fetal adrenal, fetal liver, and placenta	Seen in trisomy 21, fetal demise, steroid sulfatase deficiency; integrate with other markers.
High maternal serum AFP	Fetal protein crosses placenta into maternal blood	Open neural tube defect, abdominal wall defect, multiple gestation, incorrect dating; low AFP classically appears in trisomy 21 screening.

Preeclampsia: a placental disease with maternal endothelial manifestations

A central synthesis point is that preeclampsia originates from abnormal extravillous trophoblast invasion and inadequate remodeling of maternal spiral arteries. Normal spiral arteries become dilated, low-resistance vessels; failed remodeling causes placental ischemia-reperfusion injury and release of antiangiogenic factors including sFlt-1 and soluble endoglin, with decreased PlGF. The maternal syndrome is endothelial dysfunction: vasoconstriction, capillary leak, platelet activation, and end-organ injury.

• Diagnostic threshold: new hypertension after 20 weeks, classically blood pressure ≥140/90 mm Hg on two occasions, with proteinuria ≥300 mg/24 h or protein/creatinine ratio ≥0.3, or end-organ features.
• Severe features: blood pressure ≥160/110 mm Hg, platelets <100,000/µL, creatinine >1.1 mg/dL or doubling, transaminases elevated with right upper quadrant pain, pulmonary edema, or cerebral/visual symptoms.
• Prevention controversy: low-dose aspirin is recommended for high-risk patients. In the United States, typical dose is 81 mg daily, started between 12–28 weeks, optimally before 16 weeks. The ASPRE trial used 150 mg nightly from 11–14 weeks to 36 weeks and reduced preterm preeclampsia from 4.3% to 1.6%; Step 1 usually tests prostaglandin/thromboxane balance rather than protocol details.

Rh incompatibility: immunology plus placental transport

Maternal IgG crosses the placenta via the neonatal Fc receptor, especially in the third trimester. This is beneficial for passive immunity but dangerous in alloimmunization. An Rh-negative mother exposed to Rh-positive fetal erythrocytes can form anti-D IgG, which crosses the placenta in later pregnancies and causes extravascular hemolysis in the fetal spleen and liver, leading to anemia, high-output failure, and hydrops fetalis.

Intervention	Key number	Mechanism
Anti-D immune globulin	300 µg covers about 30 mL fetal whole blood or 15 mL fetal RBCs	Passive anti-D clears fetal Rh-positive RBCs before maternal B-cell sensitization.
Routine timing	Commonly at 28 weeks and within 72 hours postpartum if infant is Rh-positive	Prevents primary alloimmunization; it does not treat established maternal anti-D production.
Pharmacokinetics	Half-life about 24 days	Explains repeat prophylaxis after ongoing bleeding or sensitizing events.

Placental implantation disorders: anatomy predicts hemorrhage

Placental location and depth reflect decidual integrity. In placenta previa, the placenta overlies or approaches the internal cervical os, classically causing painless third-trimester bleeding; digital cervical examination is avoided until previa is excluded. In placenta accreta spectrum, deficient decidua basalis permits abnormal trophoblast attachment or invasion, especially over a prior cesarean scar.

Entity	Depth	Classic association
Accreta	Villi attach directly to superficial myometrium	Prior cesarean delivery plus placenta previa
Increta	Villi invade into myometrium	Failure of placental separation, postpartum hemorrhage
Percreta	Villi penetrate through serosa, possibly bladder	Most invasive form

Common Step 1 pitfalls

• The placental barrier is not absolute: IgG, oxygen, carbon dioxide, glucose, amino acids, many viruses, alcohol, warfarin, lithium, and many antiepileptics can cross; insulin and heparin generally do not cross appreciably because of size/charge.
• Maternal and fetal blood normally do not mix: exchange occurs across villous membranes; fetomaternal hemorrhage is pathologic or procedure-related.
• Umbilical vein versus arteries: the single umbilical vein carries oxygenated blood to the fetus; two umbilical arteries carry deoxygenated blood to the placenta.
• Placental insufficiency physiology: increased placental vascular resistance can cause fetal growth restriction, oligohydramnios, and abnormal umbilical artery Doppler with reduced, absent, or reversed end-diastolic flow.
• Biophysical profile scoring: nonstress test, fetal breathing, movement, tone, and amniotic fluid each score 0 or 2; total 8–10 is generally reassuring, 6 equivocal, and ≤4 abnormal—useful as physiology of fetal hypoxemia rather than a Step 1 management algorithm.